SCHEMBL1826280

SCHEMBL1826280

Cc1ccc(S(=O)(=O)Oc2ccccc2C(O)CNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
GAA P10253 2/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
ALDH1A1 P00352 5/20 0.39
TSHR P16473 1/20 0.39
P2RX7 Q99572 2/20 0.39
CYP3A4 P08684 2/20 0.39
HSD11B1 P28845 1/20 0.39
HSD17B3 P37058 1/20 0.39
MAPT P10636 3/20 0.39
HTT P42858 2/20 0.39
DHODH Q02127 1/20 0.38
SYK P43405 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827850 0.92 SYK (0.42) ALDH1A1HSD11B1HSD17B3MAPTDHODH
SCHEMBL1826107 0.88 LMNA (0.40) LMNAMAPK1MEN1KMT2AGAA
SCHEMBL1825628 0.86 LMNA (0.39) LMNAMAPK1MEN1KMT2AGAA
SCHEMBL1826410 0.84 SYK (0.44) SYKCA12CA1CA2CA9
SCHEMBL1825666 0.83 P2RX7 (0.44) LMNAMAPK1MEN1KMT2AGAA
SCHEMBL1826507 0.81 LMNA (0.44) LMNAMAPK1MEN1KMT2AGAA
SCHEMBL6987499 0.81 LMNA (0.44) LMNAMAPK1MEN1KMT2AGAA
SCHEMBL1825895 0.81 ALDH1A1 (0.43) LMNAMAPK1MEN1KMT2AGAA
SCHEMBL1826408 0.81 EGFR (0.46) MEN1KMT2AALDH1A1P2RX7MAPT
SCHEMBL4582959 0.80 DRD2 (0.49) LMNATSHRSYKMALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 LMNA 1802/4885MAPK1 953/4885MEN1 421/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 LMNA 1130/4885MAPK1 1335/4885MEN1 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.